Vertex Pharmaceuticals Inc
NASDAQ: VRTX
$402.14
+$9.33 (+2.4%)
Closing price May 1, 2024
The top analyst upgrades, downgrades and initiations seen on Tuesday included Boeing, Booking, Camping World, Domino's Pizza, iRobot, MetLife, Neogen, Southern Copper, Vertex Pharmaceuticals and...
Published:
Last Updated:
Here, 24/7 Wall St. includes a calendar of a few of the biggest companies expecting clinical trial and FDA updates in the first quarter of 2019.
Published:
Last Updated:
The top analyst upgrades, downgrades and initiations seen on Wednesday included Aflac, Akamai, BioMarin, Caesars Entertainment, CBS, Crocs, GW Pharma, Medtronic, Netflix and Sirius XM.
Published:
Last Updated:
The top analyst upgrades, downgrades and initiations seen on Wednesday included Apple, Baker Hughes, Biogen, FedEx, Intel, Micron Technology, Roku and Shake Shack.
Published:
Last Updated:
Here are five top health care stocks that provide investors with different avenues to invest in the sector. They all should be solid additions to growth portfolios for 2019.
Published:
Last Updated:
CRISPR Therapeutics shares made a handy gain on Thursday after the company announced a key FDA decision concerning its collaboration with Vertex Pharmaceuticals.
Published:
Last Updated:
Merrill Lynch recently highlighted sectors it considers a good opportunity now that are likely to outperform in the near term, and the sector that rated highest was biotechnology.
Published:
Last Updated:
A series of new Stifel research reports focus on three biotech companies that have upcoming clinical data that could prove to be huge.
Published:
Last Updated:
Vertex Pharmaceuticals shares saw a handy gain on Thursday after the FDA gave a nod to Vertex’s cystic fibrosis treatment.
Published:
Last Updated:
CRISPR Therapeutics shares saw a significant drop on Thursday morning after an announcement that the FDA placed a clinical hold on the Investigational New Drug Application (IND) for CTX001 for the...
Published:
Last Updated:
While these four stocks are better suited for accounts that have a higher risk tolerance, they all make good sense now and all have outstanding upside potential.
Published:
Last Updated:
Merrill Lynch has taken a look at the biotech industry and made a few picks that could play out in 2018.
Published:
Last Updated:
The top analyst upgrades, downgrades and other research calls from Friday include Albermarle, Allergan, Boston Scientific, eBay, FedEx, Gogo, LendingTree, Nokia, UPS and Vertex Pharmaceuticals.
Published:
Last Updated:
24/7 Wall St. has included a calendar of a some of the biggest companies expecting clinical trial and U.S. Food and Drug Administration (FDA) updates in February.
Published:
Last Updated:
Merrill Lynch believes that this could be the year biotechs break out. The firm has a few picks, bad and good, that it believes will play a big role in the coming year.
Published:
Last Updated: